Lv1
10 积分 2024-11-01 加入
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
6个月前
已完结
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer
6个月前
已完结
皖公网安备34019202002308
